Abstract: A magnetic confinement fusion reactor includes a host hall, and a host including a Dewar system, a cold shield system, a superconducting magnet system, a vacuum chamber system, a divertor system, a blanket system, a remote operation system, and a maintenance system. The superconducting magnet system includes a central solenoid magnet, a poloidal field magnet, and a toroidal field magnet. The central solenoid magnet is configured to provide necessary volt-seconds. The poloidal field magnet is configured to generate a poloidal magnetic field. The toroidal field magnet is configured to generate a toroidal magnetic field. The plasma is confined by the toroidal magnetic field and the poloidal magnetic field. The vacuum chamber system is provided with a neutron shielding block to protect the superconducting magnets from being damaged by fusion neutrons.

Abstract: A magnetic confinement fusion reactor includes a host hall, and a host including a Dewar system, a cold shield system, a superconducting magnet system, a vacuum chamber system, a divertor system, a blanket system, a remote operation system, and a maintenance system. The superconducting magnet system includes a central solenoid magnet, a poloidal field magnet, and a toroidal field magnet. The central solenoid magnet is configured to provide necessary volt-seconds. The poloidal field magnet is configured to generate a poloidal magnetic field. The toroidal field magnet is configured to generate a toroidal magnetic field. The plasma is confined by the toroidal magnetic field and the poloidal magnetic field. The vacuum chamber system is provided with a neutron shielding block to protect the superconducting magnets from being damaged by fusion neutrons.

Abstract: The present invention relates to crystalline forms I and II of the compound 2-N-4,6-di-O-tributyryl-D-glucosamine, preparation methods and uses thereof, wherein the crystalline forms I and II obtained from the present invention have high water solubility, crystalline stability and can be better applied in pharmacy.

Abstract: The disclosure relates to bifunctional KRAS-modulating compounds having the structure K-L-T, where K is a targeting group that binds specifically to a KRAS protein (mutant or wild-type), T is an E3-ligase binding group, and L is absent or is a bivalent linking group that connects K and T together via a covalent linkage. Compounds and pharmaceutical compositions thereof can promote degradation of KRAS protein (mutant or wild-type) in a cell and are thus useful for treating, inhibiting, and preventing KRAS-associated diseases, disorders and conditions, including cancers.

Abstract: The disclosure relates to KRAS inhibitor compounds having the structure of Formula (I), pharmaceutical compositions thereof, and methods of use thereof for inhibiting, treating, and/or preventing KRAS-associated diseases, disorders and conditions.

Abstract: The disclosure relates to KRASG12D inhibitor compounds having the structure of Formula (A) or Formula (B), pharmaceutical compositions thereof, and methods of use thereof for inhibiting, treating, and/or preventing KRASG12D mutation-associated diseases, disorders and conditions.

Abstract: The disclosure relates to bifunctional KRAS-G12D-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to KRAS-G12D protein, T is an E3-ligase binding group, and L is absent or is a bivalent linking group that connects W and T together via a covalent linkage. Compounds and pharmaceutical compositions thereof can promote degradation of the KRAS-G12D protein in a cell and are thus useful for treating, inhibiting, and preventing KRAS-G12D-associated diseases, disorders and conditions, including cancers.

Abstract: The disclosure relates to bifunctional CDK-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to a CDK protein, T is an E3-ligase binding group, and L is absent or is a bivalent linking group that connects W and T together via a covalent linkage. Compounds and pharmaceutical compositions thereof can promote degradation of one or more CDK protein in a cell and are thus useful for treating, inhibiting, and preventing CDK-associated diseases, disorders and conditions, including cancers.

Abstract: A powder injection of a donepezil semi palmoxiric acid salt, a composition containing the same and a preparation method therefor. The powder injection contains donepezil semi palmoxiric acid salt crystals having an average particle size of 2-52 ?m.

Abstract: Disclosed is a salt form of an isoquinolinone type compound as a ROCK protein kinase inhibitor and a preparation method therefor, and use of the salt form in the preparation of a medicament for treating glaucoma or ocular hypertension is further included.

Abstract: The disclosure relates to bifunctional KRAS-G12D-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to KRAS-G12D protein, T is an E3-ligase binding group, and L is absent or is a bivalent linking group that connects W and T together via a covalent linkage. Compounds and pharmaceutical compositions thereof can promote degradation of the KRAS-G12D protein in a cell and are thus useful for treating, inhibiting, and preventing KRAS-G12D-associated diseases, disorders and conditions, including cancers.

Abstract: The disclosure uses the Carter's coefficient to correct the equivalent electromagnetic air gap length. And the specific permeance on both sides of the primary core is obtained. Then, the permeance on both sides based on the structure of the primary core is calculated. An equation is established by using the continuity principle of flux, thereby obtaining the air gap magnetomotive force model of current-carrying conductor. The slot vector diagram of magnetomotive force in short primary linear machine is illustrated according to that in the rotating machine. Then, based on the winding arrangement and vector combination, the amplitude and phase of various spatial harmonic wave of the three-phase winding are obtained. Finally, the characteristics of average component distribution of the current-carrying conductor are adopted to obtain the pulsating magnetomotive force generated by the three-phase winding of the linear machine.

Abstract: Related are a JAK kinase inhibitor, a preparation method for same, and applications thereof in the field of medicine, related to the field of medicinal chemistry. Provided is a novel small molecule JAK inhibitor, which has the structure as represented by formula (II). The compound provides improved efficacy and safeness in preventing or treating a JAK-related indication.

Abstract: The disclosure uses the Carter's coefficient to correct the equivalent electromagnetic air gap length. And the specific permeance on both sides of the primary core is obtained. Then, the permeance on both sides based on the structure of the primary core is calculated. An equation is established by using the continuity principle of flux, thereby obtaining the air gap magnetomotive force model of current-carrying conductor. The slot vector diagram of magnetomotive force in short primary linear machine is illustrated according to that in the rotating machine. Then, based on the winding arrangement and vector combination, the amplitude and phase of various spatial harmonic wave of the three-phase winding are obtained. Finally, the characteristics of average component distribution of the current-carrying conductor are adopted to obtain the pulsating magnetomotive force generated by the three-phase winding of the linear machine.

Abstract: The present invention relates to a preparation method for an amide compound and an application thereof in the field of medicine. Specifically, provided by the present invention is an amide small molecule compound which is an inhibitor of Zeste gene enhancer homolog 2 (EZH2) and which may be used to prevent and/or treat EZH2-mediated related diseases, comprising tumors, myeloproliferative diseases or autoimmune diseases.

Abstract: A powder injection of a donepezil semi palmoxiric acid salt, a composition containing the same and a preparation method therefor. The powder injection contains donepezil semi palmoxiric acid salt crystals having an average particle size of 2-52 ?m.

Abstract: Provided are a preparation method for amide compounds and use thereof in medical field. Specifically, provided are small molecule amide compounds. Such compounds are inhibitors of enhancer homolog 2 (EZH2) of Zeste gene, and can be used for preventing and/or treating related diseases mediated by EZH2, including tumors, myeloproliferative diseases or autoimmune diseases.

Abstract: A bipolar bidirectional DC converter comprises at least two valve group series (101, 102) and at least six magnetic elements (103), and said valve group series are divided into a Type-I valve group series (102) and a Type-II valve group series (101) each valve group series (101, 102) comprises a high-voltage DC port, a low-voltage DC port and at least three AC ports, and each AC port is connected to a magnetic element (103); and the other ends of the magnetic elements (103), which are connected to all the AC ports in the same valve group series (101, 102), are connected.

Abstract: A powder injection of a donepezil semi palmoxiric acid salt, a composition containing the same and a preparation method therefor. The powder injection contains donepezil semi palmoxiric acid salt crystals, and the average grain size of the crystals ranges from 0.5 ?m to 100 ?m.

Abstract: A molecular marker for the selection and breeding of fine-wool sheep is disclosed. The marker is an STR marker comprising a (CA)n repeat core sequence, with n between 5 and 24 that can be obtained by PCR amplification of genomic DNA of sheep using the primers shown in SEQ ID NO: 1 and SEQ ID NO: 2 and sequencing the PCR product. When n is 17 or 18, a sheep is a fine-wool breed, and when n is 23 or 24, a sheep is a non-fine-wool breed. When the CA repeat is discontinuous, i.e., divided into two segments (e.g., 12+11 or 13+11) separated by two bases TA or GA, a sheep is a hybrid breed of fine-wool sheep and non-fine-wool sheep. Use of the marker provides methods of identifying of fine-wool sheep breeds, and efficient and accurate selection of fine-wool sheep or the hybrid offspring of fine-wool sheep for breeding.